These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2107456)

  • 1. L-carnitine replacement therapy in chronic valproate treatment.
    Melegh B; Kerner J; Acsádi G; Lakatos J; Sándor A
    Neuropediatrics; 1990 Feb; 21(1):40-3. PubMed ID: 2107456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chronic valproic acid treatment on plasma and urine carnitine levels in children: decreased urinary excretion.
    Melegh B; Kerner J; Kispál G; Acsádi G; Dani M
    Acta Paediatr Hung; 1987; 28(2):137-42. PubMed ID: 3122798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum carnitine, beta-hydroxybutyrate and ammonia levels during valproic acid therapy.
    Toksoy HB; Tanzer FN; Atalay A
    Turk J Pediatr; 1995; 37(1):25-9. PubMed ID: 7732605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carnitine metabolism in valproate-treated rats: the effect of L-carnitine supplementation.
    Nishida N; Sugimoto T; Araki A; Woo M; Sakane Y; Kobayashi Y
    Pediatr Res; 1987 Nov; 22(5):500-3. PubMed ID: 3120144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS.
    Nakajima Y; Ito T; Maeda Y; Ichiki S; Kobayashi S; Ando N; Hussein MH; Kurono Y; Sugiyama N; Togari H
    Brain Dev; 2011 Nov; 33(10):816-23. PubMed ID: 21196091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carnitine deficiency during valproic acid treatment.
    Van Wouwe JP
    Int J Vitam Nutr Res; 1995; 65(3):211-4. PubMed ID: 8830002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and muscle carnitine levels in epileptic children receiving sodium valproate.
    Anil M; Helvaci M; Ozbal E; Kalenderer O; Anil AB; Dilek M
    J Child Neurol; 2009 Jan; 24(1):80-6. PubMed ID: 19168820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carnitine disposition before and during valproate therapy in patients with epilepsy.
    Riva R; Albani F; Gobbi G; Santucci M; Baruzzi A
    Epilepsia; 1993; 34(1):184-7. PubMed ID: 8422857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.
    Pylvänen V; Pakarinen A; Knip M; Isojärvi J
    Epilepsy Behav; 2006 May; 8(3):643-8. PubMed ID: 16600693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in the carnitine metabolism in epileptic children treated with valproic acid.
    Chung S; Choi J; Hyun T; Rha Y; Bae C
    J Korean Med Sci; 1997 Dec; 12(6):553-8. PubMed ID: 9443096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores.
    Knapp AC; Todesco L; Beier K; Terracciano L; Sägesser H; Reichen J; Krähenbühl S
    J Pharmacol Exp Ther; 2008 Feb; 324(2):568-75. PubMed ID: 17986647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased fasting free fatty acids with L-carnitine in children with carnitine deficiency.
    Schwenk WF; Hale DE; Haymond MW
    Pediatr Res; 1988 May; 23(5):491-4. PubMed ID: 3290828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine.
    Kossak BD; Schmidt-Sommerfeld E; Schoeller DA; Rinaldo P; Penn D; Tonsgard JH
    Neurology; 1993 Nov; 43(11):2362-8. PubMed ID: 8232957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure.
    Triggs WJ; Gilmore RL; Millington DS; Cibula J; Bunch TS; Harman E
    Int J Clin Pharmacol Ther; 1997 Sep; 35(9):353-6. PubMed ID: 9314085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy.
    Murakami K; Sugimoto T; Nishida N; Kobayashi Y; Kuhara T; Matsumoto I
    Brain Dev; 1992 May; 14(3):178-81. PubMed ID: 1514659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of the ketogenic diet in pediatric epilepsy: effects of valproate combination therapy.
    Lyczkowski DA; Pfeifer HH; Ghosh S; Thiele EA
    Epilepsia; 2005 Sep; 46(9):1533-8. PubMed ID: 16146450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproate therapy does not deplete carnitine levels in otherwise healthy children.
    Hirose S; Mitsudome A; Yasumoto S; Ogawa A; Muta Y; Tomoda Y
    Pediatrics; 1998 May; 101(5):E9. PubMed ID: 9565442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.